PTPI OTC
Petros Pharmaceuticals, Inc.
1W: -6.2%
1M: -20.2%
3M: -23.5%
YTD: -53.1%
1Y: -85.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+13.64%)
Weekly Expected Move ±50.8%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.2M
52W Range0.002-0.025
Volume46,501
Avg Volume118,932
Beta1.96
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFady Boctor
Employees3
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2020-12-02
Websitepetrospharma.com
1185 Avenue of the Americas
New York City, NY 10036
US
New York City, NY 10036
US
973-242-0005
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WEINSTEIN ROBERT | 0 | — | 2026-06-18 | |
| WALKER WAYNE REMELL | A-Award | 375,000 | — | 2026-06-05 |
| Bernstein Bruce | A-Award | 1,875,000 | — | 2026-06-05 |
| Silverman Joshua | A-Award | 4,375,000 | — | 2026-06-05 |
| Boctor Fady | A-Award | 375,000 | — | 2026-06-05 |